Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Top-line final data from Provectus’ PV-10 phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

27 Jun 2012

Study reveals previously unknown function of Thbd-aPC pathway in radiation mitigation

New research in Nature Medicine shows that boosting a protein pathway in the body's blood making system protects mice from otherwise fatal radiation poisoning.

25 Jun 2012

CARHY announces comprehensive hematopoietic stem cell transplant service

Adding an impetus to the already existing image of Bangalore being a healthcare destination of India, Columbia Asia Referral Hospital, Yeshwanthpur (CARHY), announced comprehensive bone marrow transplant (stem cell transplant) service on Thursday.

23 Jun 2012

Novel small-molecule-inhibiting drug stops spread of breast cancer cells

Scientists have developed a small-molecule-inhibiting drug that in early laboratory cell tests stopped breast cancer cells from spreading and also promoted the growth of early nerve cells called neurites.

22 Jun 2012

Researchers identify genes that cooperate in development of medulloblastoma

St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project lifts lid on the most aggressive subtype of medulloblastoma and finds genes that cooperate in tumor development.

22 Jun 2012

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

19 Jun 2012

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced new clinical data presented in an oral presentation for ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use at the 17th Congress of the European Hematology Association (EHA).

19 Jun 2012

Study on identification of novel stem cell population in neuroblastoma to be presented at ANR conference

Dr. Eugene Kim, a pediatric surgeon with Texas Children's Cancer Center and assistant professor of surgery at Baylor College of Medicine (BCM), and Dr. Jason Shohet, chair of the Neuroblastoma Research Program at Texas Children's Cancer Center and associate professor in the Section of Hematology-Oncology at BCM, will speak at the Advances in Neuroblastoma Research (ANR) conference about the identification of a novel stem cell population in neuroblastoma.

19 Jun 2012

Pediatric treatment regime for ALL patients improves chances of long-term survival

Acute lymphoblastic leukemia (ALL), usually found in pediatric patients, is far more rare and deadly in adolescent and adult patients. According to the National Marrow Donor Program, child ALL patients have a higher than 80 percent remission rate, while the recovery rate for adults stands at only 40 percent.

18 Jun 2012

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

ASH, EHA and ECPC issue common call to action to mitigate hematologic drug shortages

The American Society of Hematology (ASH) joined the European Hematology Association (EHA) and the European Cancer Patient Coalition (ECPC) today in issuing a common call to action in an effort to mitigate shortages of hematologic drugs in the United States and around the world.

18 Jun 2012

Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL

The oral presentation will be held on June 17th 2012 by Prof. Dr. Hervé Dombret, Hospital Saint Louis, Paris (France) at the 17th Annual Meeting of European Hematology Association (EHA) in Amsterdam.

18 Jun 2012

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Pharmacyclics, Inc announced today at the 17th Congress of European Hematology Association updated results from two clinical trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

18 Jun 2012

Impressive results from blinatumomab Phase 2 study on B-precursor ALL

At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients.

18 Jun 2012

Promising results from single iron dose study for fatigue treatment in iron deficient women

Dr Micheal Hedenus of the Haematology Unit of the Sundsval Hospital in Sweden will present promising results on a study on a single iron dose for fatigue treatment in iron deficient women at the 17th Congress of the European Hematology Association in Amsterdam.

From CSL Ltd 16 Jun 2012

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).

16 Jun 2012

Quest receives FDA clearance to initiate oregovomab Phase II trial in ovarian cancer

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.

15 Jun 2012

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced updated survival data from a pivotal Phase II clinical trial of single-agent brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplant (ASCT) showing that the median overall survival has not been reached after a 26.5 month median follow-up.

14 Jun 2012

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.

10 Jun 2012

Researchers shed light on key biological events that may lead to new disease treatments

In exploring how proteins interact with crucial DNA sequences to regulate gene activity, researchers have shed light on key biological events that may eventually be manipulated to provide new disease treatments.

8 Jun 2012

Hematology News and Research

Further Reading

Top-line final data from Provectus’ PV-10 phase 2 trial on metastatic melanoma

Study reveals previously unknown function of Thbd-aPC pathway in radiation mitigation

CARHY announces comprehensive hematopoietic stem cell transplant service

Novel small-molecule-inhibiting drug stops spread of breast cancer cells

Researchers identify genes that cooperate in development of medulloblastoma

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Study on identification of novel stem cell population in neuroblastoma to be presented at ANR conference

Pediatric treatment regime for ALL patients improves chances of long-term survival

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ASH, EHA and ECPC issue common call to action to mitigate hematologic drug shortages

Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Impressive results from blinatumomab Phase 2 study on B-precursor ALL

Promising results from single iron dose study for fatigue treatment in iron deficient women

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Quest receives FDA clearance to initiate oregovomab Phase II trial in ovarian cancer

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

Researchers shed light on key biological events that may lead to new disease treatments

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo